Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol

Journal of the American College of Cardiology

Volumn 33, Issue 7, 1999, Pages 1926-1934

  Di Lenarda, Andrea ^a   Sabbadini, Gastone ^b   Salvatore, Luca ^a   Sinagra, Gianfranco ^a   Mestroni, Luisa ^c   Pinamonti, Bruno ^a   Gregori, Dario ^b   Ciani, Fulvio ^d   Muzzi, Aureo ^a   Klugmann, Silvio ^a   Camerini, Fulvio ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d Ospedale Santorio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; EXERCISE TOLERANCE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARBAZOLES; CARDIOMYOPATHY, DILATED; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE TEST; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; METOPROLOL; MYOCARDIAL CONTRACTION; OXYGEN CONSUMPTION; PROPANOLAMINES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032693742     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00134-5     Document Type: Article

References (48)

1. Packer M. The neurohormonal hypothesis a theory to explain the mechanism of disease progression in heart failure . J Am Coll Cardiol. 20:1992;248-254.
2. Sharpe N., Smith H., Murphy J., et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 337:1991;872-876.
3. Effect of enalapril on survival in patients with reduced left ventricular EF and congestive heart failure. N Engl J Med. 325:1991;293-302.
4. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
5. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
6. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 92:1995;212-218.
7. Hall S., Cigarroa C.G., Marxoux L., et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 25:1995;1154-1161.
8. Eichhorn E.J., Bristow M.R. Medical therapy can improve the biological properties of chronically failing heart. A new era in the treatment of heart failure. Circulation. 94:1996;2285-2296.
9. Di Lenarda A., Gregori D., Sinagra G., et al. Metoprolol in dilated cardiomyopathy is it possible to identify factors predictive of improvement? J Card Failure. 2:1996;87-102.
10. Gilbert E.M., Abraham W.T., Olsen S., et al. Comparative hemodynamic, left ventricular function, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 94:1996;2817-2825.
11. Report of the 1995 World Health Organization/International Society and Federation of Cardiology. Circulation. 93:1996;841-842.
12. Aretz H.T., Billigham M.E., Edwards W.D., et al. Myocarditis a histopathological definition and classification . Am J Cardiovasc Pathol. 1:1987;3-14.
13. Hanumanthu S., Butler J., Chomsky D., et al. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation. 96:1997;2842-2848.
14. Lee D.C.S., Johnson R.A., Bingham J.B., et al. Heart failure in outpatients a randomized trial of digoxin versus placebo . N Engl J Med. 306:1982;699-705.
15. Rector T.S., Kubo S.H., Cohn J.N. Patients self-assessment of their congestive heart failure, pt 2 content, reliability and validity of a new measure, the Minnesota Living With Heart Failure Questionnaire . Heart Failure. 3:1987;198-209.
16. Pinamonti B., Di Lenarda A., Sinagra G., Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography clinical, echocardiographic and hemodynamic correlations and prognostic implications . J Am Coll Cardiol. 22:1993;808-815.
17. Pinamonti B., Zecchin M., Di Lenarda A., et al. Persistence of restrictive left ventricular filling pattern in dilated cardiomyopathy an ominous prognostic sign . J Am Coll Cardiol. 29:1997;604-612.
18. Clinical exercise testing with reference to lung disease indications, standardization and interpretation strategies . Eur Respir J. 10:1997;2662-2689.
19. 1994 update. Standardization of spirometry. Am J Respir Crit Care Med. 152:1995;1107-1136.
20. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med. 152:1995;2185-2198.
21. McCullagh P, Nelder JA. Monographs on Statistics. Generalized Linear Models. London: Chapman and Hall, 1989.
22. Liang K.-Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 73:1986;13-22.
23. Oracle 7 Workgroup Server, Version 7.3 for Windows NT. Redwood City (CA): Oracle Corporation, 1996.
24. Statistical Sciences, S-PLUS User's Manual, Version 3.3 for Windows. Seattle (WA): Statsci, a division of Mathsoft Inc, 1995.
25. Di Lenarda A., Secoli G., Gregori D., et al. Long-term persistent improvement in patients with dilated cardiomyopathy treated with metoprolol. (abstr) Circulation. 92:1995;I393.
26. Yoshikawa T., Port J.D., Asano K., et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 17:(Suppl B):1996;8-16.
27. Bristow M.R. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with β-blocking agents. Am J Cardiol. 71:1993;12C-22C.
28. Ruffolo R.R., Gallai M., Hieble J.P., et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 38:1990;S82-S88.
29. Bristow M.R., Larrabee P., Minobe W. Receptor pharmacology of carvedilol in human heart. J Cardiovasc Pharmacol. 19:(Suppl 1):1992;S68-S80.
30. Yue T.-L., Cheng H.-Y., Lysko P.G., et al. Carvedilol, a new vasodilator and beta adrenoceptor, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 263:1992;92-98.
31. Ohlstein E.H., Douglas S.A., Sung C.P., et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA. 90:1993;6189-6193.
32. Rangno R.E., Langlois S., Lutterodt A. Metoprolol withdrawal phenomena mechanism and prevention . Clin Pharmacol Ther. 31:1982;8-15.
33. Waagstein F., Caidahl K., Wallentin I., et al. Long-term β-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 80:1989;551-563.
34. Tygesen H., Di Lenarda A., Andersson B., et al. Potential risk of betablockade withdrawal in congestive heart failure due to abrupt autonomic changes. Int J Cardiol. 68:1999;171-177.
35. Metra M., Nardi M., Giubbini R., Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 24:1994;1678-1687.
36. Olsen S.L., Gilbert E.M., Renlund D.G., et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure a double-blind randomized study . J Am Coll Cardiol. 25:1995;1225-1231.
37. Improvement after metoprolol in idiopathic dilated cardiomyopathy is predicted by baseline systolic blood pressure and change heart rate. (abstr) J Am Coll Cardiol. 27:1996;170A.
38. Bristow M.R., Gilbert E.M., Abraham W.T., Robertson A.D. Carvedilol in heart failure the MOCHA trial . (letter) Circulation. 96:1997;2743-2744.
39. Just H. Pathophysiological targets for beta-blocker therapy in congestive heart failure. Eur Heart J. 17:(Suppl B):1996;2-7.
40. Tawlar K.K., Bhargava B., Upasani P.T., et al. Hemodynamic predictors of early intolerance and long-term effects of propanolol in dilated cardiomyopathy. J Card Failure. 2:1996;273-277.
41. Ikram H., Fitzpatrick D. Double-blind trial of chronic oral beta-blockade in congestive cardiomyopathy. Lancet. 2:1981;490-492.
42. Swedberg K., Hjalmarson A., Holmberg S. Effects of work and acute beta-receptor blockade on myocardial noradrenaline release in congestive cardiomyopathy. Clin Cardiol. 2:1979;424-430.
43. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
44. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 29:1997;1060-1066.
45. Krum H., Sackner-Bernstein J.D., Goldsmith R.L., et al. Double blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 92:1995;1499-1506.
46. White M., Yanowitz F., Gilbert E.M., et al. Role of beta-adrenergic receptor downregulation in the peak exercise response of subjects with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 76:1995;1271-1276.
47. A randomized trial of betablockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
48. Poole-Wilson P, Cleland JGF, Hanrath P, et al. Rationale and design of the Carvedilol or Metoprolol European Trial (COMET) in patients with moderate or severe chronic heart failure. Eur J Heart Failure (in press).